Home > Quotes > ALXN
ALXN

Alexion Pharmaceuticals, Inc. Common Stock Quote & Summary Data

$139.28
*  
3.25
2.28%
Get ALXN Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading ALXN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Alexion Pharmaceuticals, Inc. Common Stock Intraday Chart




News for ALXN

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 142.305 $ 208.88
Low $ 137.40 $ 124.16

The current last sale of $139.28 is 12.18% Higher thanthe 52 week low.

P/E Ratio

ETFs with ALXN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
5.4% PowerShares Dynamic Biotech &Genome (PBE) -8.63 (-17.62%)
4.87% Market Vectors Biotech ETF (BBH) -10.90 (-9.08%)
4.3% iShares Nasdaq Biotechnology Index Fund (IBB) -46.70 (-14.50%)
1.55% SPDR Series Trust SPDR S&P Biotech ETF (XBI) -13.75 (-19.95%)
0% ProShares Ultra Nasdaq Biotechnology (BIB) -19.76 (-30.38%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on serving patients with devastating and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. In our complement franchise, Soliris is the first and only therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. PNH and aHUS are two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system. 4 -------------------------------------------------------------------------------- In our metabolic franchise, we market Strensiq for the treatment of patients with Hypophosphatasia (HPP) and Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).  ... More ...  

Risk Grade

Where does ALXN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?